Telerobotic surgery is transitioning from isolated demonstrations to broader clinical and regulatory development, according to a recent MedTech Dive report. The article, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s progress and the regulatory and infrastructure questions surrounding remote surgery. It highlighted SS Innovations International (NASDAQ: SSII) alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL).
For SS Innovations, the discussion comes as its SSi Mantra system accumulates experience in telesurgery. CEO Dr. Sudhir Srivastava told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. The company reported 195 robotic telesurgeries using the SSi Mantra as of Sept. 28, 2026, including cardiac procedures and long-distance operations. Its installed base reached 244 SSi Mantra systems as of that date, up 45% from the end of 2025, while cumulative procedures totaled 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad.
These figures underscore the company’s growing footprint in a field that could reshape access to specialized surgical care. Telesurgery allows expert surgeons to operate on patients in remote or underserved locations, potentially reducing travel and wait times for complex procedures. However, widespread adoption faces hurdles, including reliable low-latency communication networks, regulatory approval, and clinical validation. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets. Achieving those milestones would be critical for the company to compete in the U.S. and Europe, where regulatory acceptance often determines commercial success.
The MedTech Dive article’s focus on SS Innovations alongside larger players suggests that the company is gaining recognition as a notable contender in surgical robotics. As remote procedures gain ground, SS Innovations’ early experience with telesurgery could provide valuable data for regulators and clinicians evaluating the technology. The company’s newsroom at https://ibn.fm/SSII offers ongoing updates on its progress. For investors and industry observers, the convergence of telesurgery’s clinical potential and the company’s regulatory strategy makes SS Innovations a name to watch.
MissionIR, a specialized communications platform, has been assisting with syndicated content to enhance visibility for companies like SS Innovations. It operates within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and other services. As telerobotic surgery gains momentum, SS Innovations’ ability to navigate regulatory pathways and expand its clinical evidence base will determine whether it can translate early procedural volume into a durable market position.
